BMN 701

BIOLOGICAL3 trials

Sponsors

BioMarin Pharmaceutical

Conditions

Late-onset Pompe DiseasePompe Disease

Phase 1

Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

CompletedNCT01230801

BioMarin PharmaceuticalPompe Disease

Start: 2011-01-17End: 2013-03-06Updated: 2018-06-11

Phase 2

Extension Study for Patients Who Have Participated in a BMN 701 Study

TerminatedNCT01435772

BioMarin PharmaceuticalPompe Disease

Start: 2011-08-15End: 2016-09-09Updated: 2018-05-22

Phase 3

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

TerminatedNCT01924845

BioMarin PharmaceuticalLate-onset Pompe Disease

Start: 2014-04-30End: 2016-09-12Updated: 2018-06-14

Related Papers

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.

2017-08-2430 citations